FDA Tracker: 2024 Ends With Lilly’s Landmark GLP-1 Sleep Apnea Approval
What Patients Need To Know About Brain Cancer Treatments
Brain cancer remains one of medicine's most formidable challenges, requiring sophisticated treatment approaches tailored to each patient's specific situation. With advances in surgical techniques, radiation delivery, drug development and immunology, treatment options continue to evolve, offering improved outcomes and quality of life for many facing this diagnosis.
Customized treatment planningWhen confronted with a brain cancer diagnosis, patients face numerous decisions about their care path. Treatment plans vary significantly based on several critical factors including the tumor's precise location, size, specific type, and growth rate. A patient's age, overall health status and medical history also influence which approaches offer the best balance of effectiveness and tolerability.
Most patients work with a multidisciplinary team including neurosurgeons, oncologists, radiation specialists and support staff who collaborate to design comprehensive treatment strategies. This coordinated approach ensures all aspects of care work together toward the best possible outcome.
Surgery: Removing the tumorFor many brain cancer patients, surgery represents the first treatment step. The primary goal involves removing as much tumor tissue as possible while preserving surrounding healthy brain function. Complete removal sometimes proves impossible due to tumors growing in critical brain regions where surgery would cause unacceptable functional damage.
Modern surgical approaches include standard craniotomy procedures where surgeons temporarily remove a portion of the skull to access and extract the tumor. Laser surgery offers another option, using heat to destroy cancer cells while minimizing damage to nearby tissues. Some patients undergo awake brain surgery, remaining conscious during portions of the procedure so surgeons can monitor critical functions through patient responses.
While surgery often proves effective at reducing tumor burden, it rarely serves as a standalone cure. Most patients require additional treatments to eliminate remaining cancer cells not visible or accessible during the operation. The extent of surgical success significantly influences subsequent treatment planning.
Radiation therapy: Targeted destructionRadiation therapy plays a central role in brain cancer treatment, using high-energy rays to destroy cancer cells and prevent their multiplication. This approach proves particularly valuable for tumors that cannot be completely removed surgically due to location or other factors.
Several radiation approaches exist. External beam radiation therapy directs radiation at the tumor from outside the body over multiple treatment sessions. Stereotactic radiosurgery delivers highly precise radiation doses to tumors in fewer treatments, minimizing damage to surrounding healthy tissue. Proton therapy represents a newer technology using proton beams to attack cancer cells with exceptional accuracy.
Treatment effects including fatigue, headaches or cognitive difficulties may develop during or after radiation therapy. The severity of these effects typically depends on the radiation dose and brain regions treated. Most side effects improve gradually after treatment completion, though some may persist.
Chemotherapy: Systemic treatmentChemotherapy involves powerful medications that attack cancer cells throughout the body. Unlike surgery and radiation, which focus on specific areas, chemotherapy works systemically to prevent cancer spread and target cells that may have migrated from the original tumor.
Several chemotherapy medications show effectiveness against brain cancers. Temozolomide represents a widely used option that crosses the blood-brain barrier to reach tumor cells. Bevacizumab helps slow the growth of new blood vessels that tumors need for continued growth and spread.
These medications may be administered orally, through intravenous infusion, or in some cases, directly into the cerebrospinal fluid to more effectively reach the brain. Side effects range from nausea and fatigue to increased infection risk due to lowered white blood cell counts. Doctors carefully monitor patients during treatment, adjusting dosages when necessary to manage these effects.
Targeted therapy: Precision approachesTargeted therapy represents a more modern treatment approach focused on specific genes or proteins that contribute to cancer growth. These treatments interfere with cancer cell pathways while generally sparing healthy cells, often resulting in fewer side effects than traditional chemotherapy.
Recent advances include EGFR inhibitors that target mutations in the epidermal growth factor receptor found in some brain tumors. Checkpoint inhibitors boost the immune system's ability to recognize and attack cancer cells. While targeted therapy development continues for brain cancer, clinical trials show encouraging results in improving survival rates for certain tumor types.
Treatment selection depends on molecular testing of tumor tissue to identify specific targets. This personalized approach allows doctors to match patients with treatments most likely to be effective against their particular cancer.
Immunotherapy: Activating natural defensesImmunotherapy harnesses the body's own immune system to fight cancer cells. While not yet as widely used for brain cancer as other treatment forms, research continues to explore its potential against these challenging tumors.
CAR T-cell therapy genetically modifies a patient's immune cells to recognize and attack cancer. Cancer vaccines train the immune system to identify cancer cells as threats requiring elimination. These treatments remain in experimental phases for many brain cancers but offer new hope for patients with aggressive tumors.
The blood-brain barrier, which protects the brain from harmful substances but also blocks many medications, presents a particular challenge for immunotherapy. Researchers continue developing methods to overcome this barrier and deliver immune treatments effectively to brain tumors.
Clinical trials: Access to emerging treatmentsPatients who have exhausted traditional treatment options may benefit from clinical trials testing new approaches. These research studies evaluate new drugs, procedures and combination treatments to determine their effectiveness and safety before broader approval.
Clinical trials offer access to cutting-edge therapies not yet widely available. While participation involves certain risks since treatments remain under investigation, these studies provide hope for patients with limited options. The careful monitoring that accompanies trial participation represents an additional benefit.
Patients considering clinical trials should discuss potential risks and benefits thoroughly with their medical team. Not all experimental treatments prove successful, but participation contributes to scientific knowledge that may help future patients.
Managing side effects and recoveryBrain cancer treatments significantly impact physical and cognitive function. Side effects may include fatigue, memory problems, speech difficulties or motor function impairment. Many patients work with rehabilitation specialists including physical, occupational and speech therapists to regain strength and skills.
Support networks including family, friends and formal support groups play crucial roles in recovery. Mental health care helps patients cope with the emotional challenges accompanying diagnosis and treatment. Complementary approaches like meditation, nutrition counseling and exercise may help manage symptoms and improve quality of life during and after treatment.
Advancing treatment frontiersBrain cancer treatment continues evolving rapidly as researchers develop innovative approaches. Personalized medicine, which tailors treatments to a patient's specific tumor characteristics, increasingly guides treatment decisions.
Emerging research areas include nanotechnology using microscopic particles to deliver drugs directly to tumors, gene therapy modifying genetic material to fight cancer at the molecular level, and artificial intelligence applications that improve tumor detection and treatment planning.
These innovations offer hope for improved survival rates and enhanced quality of life for brain cancer patients. While complete cures remain elusive for many brain cancers, treatment advances continue extending survival and improving function for those facing this diagnosis.
Early detection, comprehensive care from specialized medical teams, and personalized treatment approaches significantly influence outcomes. For patients navigating this difficult journey, staying informed about treatment options while seeking appropriate support provides essential tools for facing brain cancer's challenges.
This story was created using AI technology.
Shaping The Future Of Cancer Treatment And Advocating For Women In STEM
Paid Content from PfizerMegan O'Meara, M.D., head of early-stage development at Pfizer Oncology, is deeply committed to scientific innovation, mentorship, and breaking barriers for the next generation of women in science, technology, engineering, and mathematics (STEM) industries. In this conversation, Megan shares her journey in oncology, leadership philosophy, and vision of a world where people with cancer live better and longer lives.
What drew you to pursue a career in oncology and what is it that inspires you most about working in this field?I've always been curious about science. My grandfather was a pediatrician, and as a child he read books to me about the history of medicine. In high school, I worked in cancer research labs, and that gave me exposure to the field from an early age. By the time I was in college, there were exciting advancements happening, including broader use of tumor profiling and targeted therapies. I felt there was a huge opportunity to transform cancer treatment, and I knew I wanted to be part of it. I pursued my medical degree and later went into academic research before transitioning to industry, where I felt I might have the broadest impact on the greatest number of people.
Women make up less than 30% of the global STEM workforce. What has your experience been as a woman in research?Being a woman in a historically male-dominated field can come with unique challenges and opportunities. There were times when I was the only woman in the room. On occasion, I felt like the only one leaving the office on time to make dinner for my family and worried about missing opportunities or important conversations that were happening when I wasn't there.
Over time, I learned to accept the situation and be confident in setting personal boundaries. I inserted myself in different ways and advanced my career without losing who I am. I developed the confidence to be me — bringing my most authentic and whole self to work. Now, I encourage and empower other women to do the same.
As an industry, there's still a long way to go. At a recent oncology conference, research showed that men presenting were introduced as "Dr." while women were introduced by their first names. It seems nuanced, but it reflects a larger issue. Even in a field like oncology, where we pride ourselves on progress, bias still exists in subtle but pervasive ways. Things are improving, but they're not where they should be yet. That's why I feel so strongly about uplifting other women and creating opportunities for women in science.
How are you working to change the research field to be more inclusive and supportive of women?There were many people, particularly female leaders, throughout my career who saw my potential and championed my advancement. I try to do the same for all my team at Pfizer, including the talented women that work with me. I mention their names when I'm in a room with other leaders; I look for opportunities that will showcase their potential.
Outside of work, I volunteer at my daughter's elementary school to organize events that engage students with science, such as bringing in Pfizer scientists to demonstrate lab techniques like DNA isolation and talk about how science can be applied to areas they are interested in. Studies show that girls start losing interest in science around age 12, so, if we can work to address that early, it can make a difference in improving female representation in STEM fields.
I'm also active in the Society for Immunotherapy in Cancer (SITC) Women in Cancer Immunotherapy Network. I've spoken about my journey in research at their events, which are often attended by many women in both academia and industry who are at a crossroads in their career. They're wondering, "Can I do this?" Hearing people's stories about how they made it work can be incredibly inspiring.
As head of the division at Pfizer Oncology responsible for developing innovative cancer treatments, what excites you most about the work your team is currently doing?Right now, I'm particularly excited about our work in antibody-drug conjugates (ADCs). ADCs are innovative cancer medicines that specifically target cancer cells and deliver cancer-killing drugs directly to tumors, while sparing more of the healthy cells in the body.
ADCs have been the foundation of my career, having worked in the space for almost 15 years. This depth of experience, knowledge, and history is being applied now to what we're doing at Pfizer to advance the field. And we've had a huge impact already — bringing treatments to people with blood cancer for the first time in decades and significantly changing the standard of care across tumor types.
Now, as a company, we're asking, "How do we make ADCs even safer and more effective?" We're exploring new drug linkers, different payloads, and novel combinations, all with the goal of giving patients better options. This kind of innovation is why I pursued a career in STEM — it's tremendously fulfilling to be bringing us closer to a world where people with cancer live better and longer lives.
How is Pfizer uniquely positioned to make progress in cancer treatment?I like to say Pfizer embodies a spirit of innovation and we have some of the most brilliant and dedicated scientists I've ever worked with. It's rare to work at a company, even in big pharma, that has demonstrated leadership across multiple modalities of science the way Pfizer has. We're constantly learning, adapting, and investing in what's next across a wide pipeline of products. It's an amazing powerhouse to be a part of.
For me, our success is also due to a culture — set by our executives — where each person has the opportunity to thrive. Chris Boshoff, chief scientific officer and president, R&D, is passionate about showcasing the team and giving people opportunities. I've experienced the same from other leaders. When I first joined Pfizer, Sally Susman, executive vice president and chief corporate affairs officer, introduced herself and said, "Next time you're in New York, come meet my team." She brought me into her leadership meeting and helped me build connections. These are just two of many people that have gone out of their way to create an environment where I am able to bring my best self to work, and I am doing the same to ensure my team of scientists has everything they need to succeed.
What do you hope for the future of women in STEM?I hope that in 20 years, women don't have to navigate as many barriers. I hope everyone can bring their whole self to the table without feeling like they need to sacrifice a piece of their personal life to succeed. Instead of feeling impostor syndrome around big opportunities, I hope women ask themselves, "Why not me?"
We still have work to do, but I truly believe we're making progress. By supporting women, we're supporting a better industry and better science.
Learn more about Pfizer Oncology at Let's Outdo Cancer.
(Photo by Ashi (Adobe Stock))
Understanding Metastatic Breast Cancer: An In-Depth Look
Metastatic breast cancer (MBC) or stage IV breast cancer is when cancer spreads beyond the breast and regional lymph nodes to distant sites like bones, liver, lungs or brain. Breast cancer cells travel through the blood stream and establish new tumors in various organs. This stage of breast cancer is a big clinical challenge as it's not curable in most cases. But with systemic therapy, targeted therapies and personalized treatment, many patients are living longer and better.
Despite all these advances, metastatic breast cancer still accounts for a big chunk of cancer morbidity and mortality worldwide. This article will go into the epidemiology, prognosis, metastatic patterns, treatment options and emerging trends, so clinicians can apply to patient care.
Table of Contents
Epidemiology and PrognosisGlobally, metastatic breast cancer diagnosed at initial presentation is 6-10% in high income countries. Over 685,000 women worldwide live with metastatic breast cancer, that's the burden of the disease and the growing number of patients who are living longer due to better treatments. But this percentage is higher in low and middle income countries because of delayed diagnosis and limited access to healthcare. Screening and early detection have reduced stage IV diagnosis in developed countries but metastatic recurrence is common even after treatment of earlier stage disease.
PrognosisPrognosis for metastatic breast cancer is variable depending on factors like tumor subtype, metastatic site, response to treatment and extent of cancer growth:
Breast cancer progression is when cancer cells break away from the primary tumor or nearby lymph nodes and enter the bloodstream or lymphatic system. These rogue cells can travel to other parts of the body and establish new tumors. This process is called metastasis and can happen at any stage of breast cancer but is more common in advanced stages. Understanding how cancer cells disseminate is key to developing treatment strategies and improving patient outcomes.
The pattern of metastatic spread in secondary breast cancer affects prognosis and treatment decisions. Common sites are:
Recognizing secondary breast cancer symptoms is important as symptoms can vary depending on the metastatic site and will lead to further testing and evaluation by healthcare professionals.
Symptoms and DiagnosisSymptoms of metastatic breast cancer can vary greatly depending on where the cancer has spread. Common symptoms are:
If you experience any of these symptoms, see a doctor immediately. Early detection and treatment of metastatic breast cancer can improve prognosis and quality of life.
TreatmentSystemic TherapySystemic therapy is the main stay of management for metastatic breast cancer patients. Treatment is tailored to the tumor biology, hormone receptor status, HER2 expression and genetic markers like BRCA mutations.
Hormone TherapyWhile systemic therapy is first line, local therapy can provide palliation or address oligometastatic disease:
Oligometastatic disease is defined as limited metastatic burden, typically less than 5 sites. Survival outcomes for oligometastatic disease patients can vary greatly depending on the extent of treatment. For example the SABR-COMET trial showed a 13 month improvement in overall survival when stereotactic body radiotherapy (SBRT) was added to standard care, so there is potential for durable disease control in select patients. These studies emphasize the importance of precise imaging and multidisciplinary evaluation to identify patients for aggressive therapy. Precise imaging is key in metastatic breast cancer to identify patients for aggressive therapy. Aggressive approaches including surgery and stereotactic body radiotherapy (SBRT) have been explored to achieve durable control. But more trials are needed to confirm the benefit of these strategies.
Emerging Data and New TherapiesEarly data suggests breast reconstruction in de novo metastatic disease patients may be associated with longer survival. But more data is needed to account for potential biases (healthier patients are more likely to get reconstructed).
Systemic therapies:Next generation sequencing (NGS) allows clinicians to identify actionable mutations and get patients into clinical trials of targeted therapy. Personalized medicine is becoming increasingly important in metastatic breast cancer management. [6]
Patient Care: Psychosocial ConsiderationsLiving with metastatic breast cancer is mentally and emotionally challenging for patients. Common issues:
Interdisciplinary teams including oncology social workers and mental health professionals are key to addressing these issues.
Palliative and End of Life CareSince metastatic breast cancer is incurable for most patients, palliative care is important for:
While metastatic breast cancer remains a clinical challenge, treatment and personalized medicine have improved outcomes for many patients. Metastasis is when cancer cells travel to other parts of the body and create tumors. The prognosis of metastatic breast cancer varies based on the site of the tumors. Of the types of metastasis, bone metastasis has the best prognosis, while visceral and brain metastasis have the worst prognosis. The pattern and biology of the tumor, along with personalized medicine, drive the most positive outcomes.
References[1] Soran, A., Ozmen, V., Ozbas, S., Karanlik, H., Muslumanoglu, M., Igci, A., Canturk, Z., Utkan, Z., Ozaslan, C., Evrensel, T., Uras, C., Aksaz, E., Soyder, A., Ugurlu, U., Col, C., Cabioglu, N., Bozkurt, B., Uzunkoy, A., Koksal, N., Gulluoglu, B. M., … Johnson, R. (2018). Randomized Trial Comparing Resection of Primary Tumor with No Surgery in Stage IV Breast Cancer at Presentation: Protocol MF07-01. Annals of surgical oncology, 25(11), 3141–3149. Https://doi.Org/10.1245/s10434-018-6494-6
[2] Palma, D. A., Olson, R., Harrow, S., Gaede, S., Louie, A. V., Haasbeek, C., Mulroy, L., Lock, M., Rodrigues, G. B., Yaremko, B. P., Schellenberg, D., Ahmad, B., Senthi, S., Swaminath, A., Kopek, N., Liu, M., Moore, K., Currie, S., Schlijper, R., Bauman, G. S., … Senan, S. (2020). Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 38(25), 2830–2838. Https://doi.Org/10.1200/JCO.20.00818
[3] Turner, N. C., Slamon, D. J., Ro, J., Bondarenko, I., Im, S. A., Masuda, N., Colleoni, M., DeMichele, A., Loi, S., Verma, S., Iwata, H., Harbeck, N., Loibl, S., André, F., Puyana Theall, K., Huang, X., Giorgetti, C., Huang Bartlett, C., & Cristofanilli, M. (2018). Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer. The New England journal of medicine, 379(20), 1926–1936. Https://doi.Org/10.1056/NEJMoa1810527
[4] Schmid, P., Adams, S., Rugo, H. S., Schneeweiss, A., Barrios, C. H., Iwata, H., Diéras, V., Hegg, R., Im, S. A., Shaw Wright, G., Henschel, V., Molinero, L., Chui, S. Y., Funke, R., Husain, A., Winer, E. P., Loi, S., Emens, L. A., & IMpassion130 Trial Investigators (2018). Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. The New England journal of medicine, 379(22), 2108–2121. Https://doi.Org/10.1056/NEJMoa1809615
[5] Robson, M., Im, S. A., Senkus, E., Xu, B., Domchek, S. M., Masuda, N., Delaloge, S., Li, W., Tung, N., Armstrong, A., Wu, W., Goessl, C., Runswick, S., & Conte, P. (2017). Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation. The New England journal of medicine, 377(6), 523–533. Https://doi.Org/10.1056/NEJMoa1706450
[6] Harbeck, N., & Gnant, M. (2017). Breast cancer. Lancet (London, England), 389(10074), 1134–1150. Https://doi.Org/10.1016/S0140-6736(16)31891-8
[7] Sledge, G. W., Jr, Toi, M., Neven, P., Sohn, J., Inoue, K., Pivot, X., Burdaeva, O., Okera, M., Masuda, N., Kaufman, P. A., Koh, H., Grischke, E. M., Frenzel, M., Lin, Y., Barriga, S., Smith, I. C., Bourayou, N., & Llombart-Cussac, A. (2017). MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 35(25), 2875–2884. Https://doi.Org/10.1200/JCO.2017.73.7585
[8] André, F., Ciruelos, E., Rubovszky, G., Campone, M., Loibl, S., Rugo, H. S., Iwata, H., Conte, P., Mayer, I. A., Kaufman, B., Yamashita, T., Lu, Y. S., Inoue, K., Takahashi, M., Pápai, Z., Longin, A. S., Mills, D., Wilke, C., Hirawat, S., Juric, D., … SOLAR-1 Study Group (2019). Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer. The New England journal of medicine, 380(20), 1929–1940. Https://doi.Org/10.1056/NEJMoa1813904
[9] Litton, J. K., Rugo, H. S., Ettl, J., Hurvitz, S. A., Gonçalves, A., Lee, K. H., Fehrenbacher, L., Yerushalmi, R., Mina, L. A., Martin, M., Roché, H., Im, Y. H., Quek, R. G. W., Markova, D., Tudor, I. C., Hannah, A. L., Eiermann, W., & Blum, J. L. (2018). Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation. The New England journal of medicine, 379(8), 753–763. Https://doi.Org/10.1056/NEJMoa1802905
Comments
Post a Comment